17:53 , Oct 19, 2018 |  BC Week In Review  |  Clinical News

Priority review for Imbruvica-Gazyva combo to treat CLL, SLL

AbbVie Inc. (NYSE:ABBV) said FDA accepted and granted Priority Review to an sNDA for Imbruvica ibrutinib plus Gazyva obinutuzumab to treat chronic lymphocytic leukemia or small lymphocytic leukemia in the first-line setting. AbbVie said the...
14:44 , Oct 17, 2018 |  BC Extra  |  Company News

Priority Review for Imbruvica-Gazyva combo to treat CLL, SLL

AbbVie Inc. (NYSE:ABBV) said FDA accepted and granted Priority Review to an sNDA for Imbruvica ibrutinib plus Gazyva obinutuzumab to treat chronic lymphocytic leukemia or small lymphocytic leukemia in the first-line setting. AbbVie said the...
22:26 , Oct 12, 2018 |  BC Extra  |  Financial News

Biotech stocks ride tech rally

Biotech indexes ended the week on a positive note but it wasn’t enough to salvage the week. The NASDAQ Biotechnology Index (NBI), SPDR S&P Biotech ETF (XBI), BioCentury 100 and NYSE Arca Biotechnology Index (BTK)...
18:10 , Oct 12, 2018 |  BC Week In Review  |  Clinical News

Phase II data for Merck's Btk inhibitor highlighted at ECTRIMS

Merck KGaA (Xetra:MRK) reported 24-week data from a Phase II trial to treat relapsing multiple sclerosis showing that evobrutinib (M2951) reduced the mean total number of gadolinium-enhancing T1 lesions by up to 2.7 over placebo....
12:15 , Oct 12, 2018 |  BC Extra  |  Clinical News

Phase II data for Merck's Btk inhibitor highlighted at ECTRIMS

Merck KGaA (Xetra:MRK) reported 24-week data from a Phase II trial to treat relapsing multiple sclerosis showing that evobrutinib (M2951) reduced the mean total number of gadolinium-enhancing T1 lesions by up to 2.7 over placebo....
23:40 , Oct 10, 2018 |  BC Extra  |  Financial News

Biotech slides with broader market

Biotech indexes fell Wednesday, mostly in line with the broader markets, marking significant mid-week losses. The moves come among continued trade tensions with China and follows the Federal Reserve raising interest rates for the third...
01:19 , Oct 6, 2018 |  BioCentury  |  Finance

In sight of uncharted territory

Strong growth from small- and mid-caps coupled with a late run from large cap biotechs have pushed the sector within sight of its all-time high in 2015. Some buysiders now are seeing red flags of...
20:17 , Oct 5, 2018 |  BC Week In Review  |  Company News

Blackstone acquiring Clarus; Galakatos to lead PE firm's new life sciences unit

Blackstone (NYSE:BX) will acquire life sciences investment firm Clarus and launch a new unit, Blackstone Life Sciences. Clarus co-founder and Managing Director Nick Galakatos, who will lead the unit, told BioCentury the group intends to...
20:14 , Oct 4, 2018 |  BC Extra  |  Company News

Blackstone acquiring Clarus; Galakatos to lead PE firm's new life sciences unit

Blackstone (NYSE:BX) will acquire life sciences investment firm Clarus and launch a new unit, Blackstone Life Sciences. Clarus co-founder and Managing Director Nick Galakatos, who will lead the unit, told BioCentury the group intends to...
23:25 , Oct 3, 2018 |  BC Innovations  |  Distillery Therapeutics

Autoimmune disease; inflammation

INDICATION: Rheumatoid arthritis (RA); allergy...